Partners & Research

Life-giving alliances and U.S. Clinical Research

An open exchange of ideas unifies our efforts as we continue to pioneer the “liquid biopsy” market, proving theory with evidence.

Anpac Bio is working with partners worldwide.

Anpac Bio has partnered with respected medical and research institutions, worldwide, conducting multiple research studies and clinical trials. Anpac Bio scientists have published and presented verified research studies at the American Society of Clinical Oncology (ASCO) and the World Nobel Prize Laureate Summit on Biomedical Sciences, among others.

Become a partner

On-going Clinical Trials

Anpac Bio is working with internationally-respected medical institutions to develop R&D investigations and formal clinical trials in the United States. These trials are in addition to the 100,000+ cases that have successfully been conducted globally.

Current Trials

A multi-disciplinary team of scientists and engineers at the forefront of their fields.

Co-Founder, Dr. Chris Yu and Dr. Herbert Yu are bringing together a multi-national team of medical, biomedical and nanotechnology scientists, and engineering experts. Their unique, cross-disciplinary approach combines numerous fields of science, medicine and engineering to achieve vastly superior early cancer screening and detection technology.

About Anpac

“game changing”

Read about our CDA technology at the Nobel Prize Laureate Summit on Biomedical Science (NPLS) publications.

Read the full article

Quick Links

Contact Information

Anpac Technology USA (Anpac Bio)
3 Spring House Innovation Park, Suite 150
Ambler, PA 19002

Email: [email protected]

Phone Number: +1 (267) 810-6776

Anpac Bio-Medical Science Co., Ltd.

Anpac Bio is a biotechnology company focusing on early cancer screening and detection and marketing a suite of cancer detection tests, including CDA (Cancer differentiation analysis), bio-chemistry, immunology, and genomics tests. Anpac has developed a multi-cancer screening and detection test that uses innovative, patented Cancer Differentiation Analysis (CDA) technology and proprietary cancer-detection device.